In clinical practice, we observed that some prolactinoma patients receiving bromocriptine (BRC) treatment fail to achieve normalized serum prolactin levels, with tumor size reductions remaining below 30%, indicating resistance to BRC therapy. The gene discussed is PRL; the disease is neoplasm.